ClinicalTrialsFinder

HR Positive/HER2 Low Breast Cancer Clinical Trials in Shanghai

1 recruitingShanghai, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

HR Positive/HER2 Low Breast Cancer
First Affiliated Hospital of Zhejiang University111 enrolled5 locationsNCT07383818